2023-507873-16-00
尚未招募
Phase III and phase IV (Integrated)
Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastatique non résécable : étude de phase 3 randomisée multicentrique en double aveugle.
概览
- 阶段
- Phase III and phase IV (Integrated)
- 状态
- 尚未招募
- 入组人数
- 122
- 试验地点
- 19
- 主要终点
- The primary endpoint is progression-free survival (PFS)
概览
简要总结
The primary objective is to evaluate the effect of doubling the dose of bevacizumab in patients with mCRC treated in 1st line with a bevacizumab-based chemotherapy regimen whose trough serum concentration of bevacizumab is ≤ 15.5 mg /L on day 14 of the first administration of bevacizumab on progression-free survival (PFS).
研究设计
- 分配方式
- Randomized
- 主要目的
- Suivi
- 盲法
- Double (Subject, Monitor, Investigator, Analyst)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Adult patients ≥18 years old
- •Signature of free, written and informed consent by the patient;
- •Affiliation to a French social security system.
- •Randomization criteria in the experimental phase: - 1st residual serum concentration (Cres) of bevacizumab ≤ 15.5 mg/L measured just before the 2nd infusion of bevacizumab (D14).
- •ECOG Performance status (PS) 0-2
- •Having a histologically proven metastatic colorectal adenocarcinoma (on primary tumor and/or metastases) that is inoperable and well documented, i.e. not compatible with complete oncological resection at inclusion
- •For whom treatment with bevacizumab is indicated
- •For women of childbearing age: effective contraception
- •No prior treatment with palliative chemotherapy for metastatic disease (in case of adjuvant treatment, interval between the end of chemotherapy and relapse > 6 months)
- •At least one evaluable or measurable lesion assessed by computed tomography (CT) according to RECIST v1.1 criteria
排除标准
- •Patient with a known contraindication to first-line chemotherapy based on bevacizumab
- •Patient under guardianship, curatorship or safeguard of justice.
- •Inadequate hematological, hepatic or renal function
- •Contraindication to bevacizumab (major surgery within 28 days, risk of arterial thrombosis, risk of bleeding, deep vein thrombosis without effective anticoagulant treatment or unbalanced anticoagulant treatment)
- •In the event of brain metastases, their treatment (surgery and/or radiotherapy) must have been completed more than 4 weeks before the first cycle of chemotherapy under study
- •Serious non-healing wound, active ulcer or untreated bone fracture: ° Other neoplasia (recent or current history), except carcinoma in situ of the cervix treated adequately, localized basal cell or squamous cell carcinoma of the skin managed with curative intent ° Neoplasia in complete remission for more than 5 years.
- •Other illness, which, according to the doctor, is life-threatening to the patient and/or which is uncontrolled
- •Primary tumor present and symptomatic (occlusion, hemorrhage)
- •Pregnant or breastfeeding women
- •Patients unable to give consent
结局指标
主要结局
The primary endpoint is progression-free survival (PFS)
The primary endpoint is progression-free survival (PFS)
次要结局
- 1. Safety profile defined by the number of adverse events classified according to the NCI-CTCAE5.0 classification. Particularly focused on AEs which are known to be linked to bevacizumab: hypertension, proteinuria, etc.
- 2. Overall survival defined as the time elapsed between the date of randomization and death (all causes),
- 3. Rate of best objective tumor response according to RECIST v1.1 criteria (evaluated over the entire duration of treatment).
- 4. Depth of tumor response defined as the percentage of tumor reduction observed at the lowest point.
- 5. Secondary resection of metastases (assessed over the entire treatment period)
- 6. Quality of life: EORTC QLQ-C30 and EQ5D-5L.
- 7. Serum concentrations of bevacizumab on day 14 of the first administration, and at 2 months from randomization (= 3 months from day 1 of the first cycle).
- 8. Medical-economic analysis: estimation of the Differential Cost-Utility Ratio expressed as cost per QALY gained (year of life provided on quality) and the Differential Cost-Effectiveness Ratio expressed as cost per year of life gained.
研究者
Pr Thierry LECOMTE
Scientific
Centre Hospitalier Regional Universitaire De Tours
研究点 (19)
Loading locations...
相似试验
招募中
2 期
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)2022-502743-35-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.52
已完成
不适用
Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell NeoplasmsPER-015-08EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),
进行中（未招募）
不适用
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program.metastatic colo-rectal carcinomaMedDRA version: 6.1Level: PTClassification code 10061045EUCTR2004-000315-26-ITROCHE1,500
进行中（未招募）
1 期
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. - First BEATMetastatic cancer of the colon or rectum.EUCTR2004-000315-26-SKF.Hoffmann-La Roche Ltd.2,000
进行中（未招募）
不适用
First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. An Expanded Access Program. - First BEATMetastatic cancer of the colon or rectum.EUCTR2004-000315-26-HUF. Hoffmann-La Roche Ltd.2,000